Advertisement

Topics

Netscientific business Vortex Bio kicks off lung cancer proof of concept trial

05:18 EDT 24 May 2017 | Proactive Investors

NetScientific PLC (LON:NSCI) portfolio company Vortex Biosciences has initiated two clinical research studies with Californian university UCLA in patients with Non-Small Cell Lung Cancer (NSCLC). These studies are designed to provide proof of principle that biomarkers used for tumour biopsises can be adapted for circulating tumour cells (CTCs). This first 60 patient study is intended to determine if cancer causing EGFR mutations can be identified in CTCs isolated and collected using Vortex’sVTX-1 Liquid Biopsy System from NSCLC patient samples. The second 100 NSCLC patient study is intended to show CTCs isolated using the VTX-1 Liquid Biopsy System are compatible with the PD-L1 biomarker, which can help identify patients suitable for immunotherapy treatment. Francois  Martelet, who is chairman of Vortex a well as being NetScientific’s chief executive, said  said: “These two proof of principle clinical research studies, in collaboration with UCLA, are a vital step in clinically validating and thus commercialising the company's first product, the VTX-1 system.”

Original Article: Netscientific business Vortex Bio kicks off lung cancer proof of concept trial

NEXT ARTICLE

More From BioPortfolio on "Netscientific business Vortex Bio kicks off lung cancer proof of concept trial"

Quick Search
Advertisement
 

Relevant Topics

Clinical Research Organization
Contract Research Organization (CRO) provide research services outsourced on a contract basis to the pharmaceutical, biotechnology, healthcare and medical device industries: biopharmaceutical development biologic assay development commercial...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...